APO Research
Talk to an analyst

APO RESEARCH · REPORT

Treatment of Blastic-Phase CML

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Treatment of Blastic-Phase CML Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025195 pages

Choose your research edition.

Industry ResearchTreatment of Blastic-Phase CML Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Treatment of Blastic-Phase CML Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Treatment of Blastic-Phase CML Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Treatment of Blastic-Phase CML Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Treatment of Blastic-Phase CML Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Treatment of Blastic-Phase CML market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Treatment of Blastic-Phase CML is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Treatment of Blastic-Phase CML is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Treatment of Blastic-Phase CML is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Treatment of Blastic-Phase CML is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Treatment of Blastic-Phase CML include Chia Tai Tianqing Pharmaceutical, CSPC Ouyi Pharmaceutical, Qilu Pharmaceutical, Lunan Pharmaceutical, Hansoh Pharmaceutical, HanHui Pharmaceuticals, Takeda Pharmaceuticals, Sanofi and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Treatment of Blastic-Phase CML market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Treatment of Blastic-Phase CML and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Treatment of Blastic-Phase CML sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Treatment of Blastic-Phase CML market size, projected growth trends, production technologies, key applications, and end-use industries.

Treatment of Blastic-Phase CML Segment by Company

Chia Tai Tianqing Pharmaceutical

CSPC Ouyi Pharmaceutical

Qilu Pharmaceutical

Lunan Pharmaceutical

Hansoh Pharmaceutical

HanHui Pharmaceuticals

Takeda Pharmaceuticals

Sanofi

Pfizer

Novartis

Dr. Reddy's Laboratories

Bristol Myers Squibb

Beacon Pharmaceuticals

Apotex

Treatment of Blastic-Phase CML Segment by Type

Targeted Therapy with TKIs

Allogeneic BMT or SCT

Chemotherapy

Others

Treatment of Blastic-Phase CML Segment by Application

Hospitals

Clinics

Others

Treatment of Blastic-Phase CML Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Treatment of Blastic-Phase CML market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Treatment of Blastic-Phase CML and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Treatment of Blastic-Phase CML.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Treatment of Blastic-Phase CML market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Treatment of Blastic-Phase CML manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Treatment of Blastic-Phase CML in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Treatment of Blastic-Phase CML in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Treatment of Blastic-Phase CML Industry Trends Table 2. Treatment of Blastic-Phase CML Industry Drivers Table 3. Treatment of Blastic-Phase CML Industry Opportunities and Challenges Table 4. Treatment of Blastic-Phase CML Industry Restraints Table 5. Global Treatment of Blastic-Phase CML Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Treatment of Blastic-Phase CML Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Treatment of Blastic-Phase CML Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Treatment of Blastic-Phase CML Sales Market Share by Manufacturers Table 9. Global Treatment of Blastic-Phase CML Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Treatment of Blastic-Phase CML Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Treatment of Blastic-Phase CML Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Treatment of Blastic-Phase CML Manufacturers, Product Type & Application Table 13. Global Treatment of Blastic-Phase CML Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Treatment of Blastic-Phase CML by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Targeted Therapy with TKIs Table 17. Major Manufacturers of Allogeneic BMT or SCT Table 18. Major Manufacturers of Chemotherapy Table 19. Major Manufacturers of Others Table 20. Global Treatment of Blastic-Phase CML Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Treatment of Blastic-Phase CML Sales by Type (2021-2026) & (K Units) Table 22. Global Treatment of Blastic-Phase CML Sales by Type (2027-2032) & (K Units) Table 23. Global Treatment of Blastic-Phase CML Sales Market Share by Type (2021-2026) Table 24. Global Treatment of Blastic-Phase CML Sales Market Share by Type (2027-2032) Table 25. Global Treatment of Blastic-Phase CML Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Treatment of Blastic-Phase CML Revenue by Type (2021-2026) & (K Units) Table 27. Global Treatment of Blastic-Phase CML Revenue by Type (2027-2032) & (K Units) Table 28. Global Treatment of Blastic-Phase CML Revenue Market Share by Type (2021-2026) Table 29. Global Treatment of Blastic-Phase CML Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospitals Table 31. Major Manufacturers of Clinics Table 32. Major Manufacturers of Others Table 33. Global Treatment of Blastic-Phase CML Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Treatment of Blastic-Phase CML Sales by Application (2021-2026) & (K Units) Table 35. Global Treatment of Blastic-Phase CML Sales by Application (2027-2032) & (K Units) Table 36. Global Treatment of Blastic-Phase CML Sales Market Share by Application (2021-2026) Table 37. Global Treatment of Blastic-Phase CML Sales Market Share by Application (2027-2032) Table 38. Global Treatment of Blastic-Phase CML Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Treatment of Blastic-Phase CML Revenue by Application (2021-2026) & (K Units) Table 40. Global Treatment of Blastic-Phase CML Revenue by Application (2027-2032) & (K Units) Table 41. Global Treatment of Blastic-Phase CML Revenue Market Share by Application (2021-2026) Table 42. Global Treatment of Blastic-Phase CML Revenue Market Share by Application (2027-2032) Table 43. Global Treatment of Blastic-Phase CML Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Treatment of Blastic-Phase CML Sales by Region (2021-2026) & (K Units) Table 45. Global Treatment of Blastic-Phase CML Sales Market Share by Region (2021-2026) Table 46. Global Treatment of Blastic-Phase CML Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Treatment of Blastic-Phase CML Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Treatment of Blastic-Phase CML Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Treatment of Blastic-Phase CML Sales by Country (2021-2026) & (K Units) Table 50. North America Treatment of Blastic-Phase CML Sales by Country (2027-2032) & (K Units) Table 51. Europe Treatment of Blastic-Phase CML Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Treatment of Blastic-Phase CML Sales by Country (2021-2026) & (K Units) Table 53. Europe Treatment of Blastic-Phase CML Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Treatment of Blastic-Phase CML Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Treatment of Blastic-Phase CML Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Treatment of Blastic-Phase CML Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Treatment of Blastic-Phase CML Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Treatment of Blastic-Phase CML Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Treatment of Blastic-Phase CML Sales by Country (2027-2032) & (K Units) Table 60. Global Treatment of Blastic-Phase CML Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Treatment of Blastic-Phase CML Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Treatment of Blastic-Phase CML Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Treatment of Blastic-Phase CML Revenue Market Share by Region (2021-2026) Table 64. Global Treatment of Blastic-Phase CML Revenue Market Share by Region (2027-2032) Table 65. Chia Tai Tianqing Pharmaceutical Company Information Table 66. Chia Tai Tianqing Pharmaceutical Business Overview Table 67. Chia Tai Tianqing Pharmaceutical Treatment of Blastic-Phase CML Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Chia Tai Tianqing Pharmaceutical Treatment of Blastic-Phase CML Product Portfolio Table 69. Chia Tai Tianqing Pharmaceutical Recent Development Table 70. CSPC Ouyi Pharmaceutical Company Information Table 71. CSPC Ouyi Pharmaceutical Business Overview Table 72. CSPC Ouyi Pharmaceutical Treatment of Blastic-Phase CML Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. CSPC Ouyi Pharmaceutical Treatment of Blastic-Phase CML Product Portfolio Table 74. CSPC Ouyi Pharmaceutical Recent Development Table 75. Qilu Pharmaceutical Company Information Table 76. Qilu Pharmaceutical Business Overview Table 77. Qilu Pharmaceutical Treatment of Blastic-Phase CML Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Qilu Pharmaceutical Treatment of Blastic-Phase CML Product Portfolio Table 79. Qilu Pharmaceutical Recent Development Table 80. Lunan Pharmaceutical Company Information Table 81. Lunan Pharmaceutical Business Overview Table 82. Lunan Pharmaceutical Treatment of Blastic-Phase CML Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Lunan Pharmaceutical Treatment of Blastic-Phase CML Product Portfolio Table 84. Lunan Pharmaceutical Recent Development Table 85. Hansoh Pharmaceutical Company Information Table 86. Hansoh Pharmaceutical Business Overview Table 87. Hansoh Pharmaceutical Treatment of Blastic-Phase CML Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Hansoh Pharmaceutical Treatment of Blastic-Phase CML Product Portfolio Table 89. Hansoh Pharmaceutical Recent Development Table 90. HanHui Pharmaceuticals Company Information Table 91. HanHui Pharmaceuticals Business Overview Table 92. HanHui Pharmaceuticals Treatment of Blastic-Phase CML Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. HanHui Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolio Table 94. HanHui Pharmaceuticals Recent Development Table 95. Takeda Pharmaceuticals Company Information Table 96. Takeda Pharmaceuticals Business Overview Table 97. Takeda Pharmaceuticals Treatment of Blastic-Phase CML Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Takeda Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolio Table 99. Takeda Pharmaceuticals Recent Development Table 100. Sanofi Company Information Table 101. Sanofi Business Overview Table 102. Sanofi Treatment of Blastic-Phase CML Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Sanofi Treatment of Blastic-Phase CML Product Portfolio Table 104. Sanofi Recent Development Table 105. Pfizer Company Information Table 106. Pfizer Business Overview Table 107. Pfizer Treatment of Blastic-Phase CML Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Pfizer Treatment of Blastic-Phase CML Product Portfolio Table 109. Pfizer Recent Development Table 110. Novartis Company Information Table 111. Novartis Business Overview Table 112. Novartis Treatment of Blastic-Phase CML Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Novartis Treatment of Blastic-Phase CML Product Portfolio Table 114. Novartis Recent Development Table 115. Dr. Reddy's Laboratories Company Information Table 116. Dr. Reddy's Laboratories Business Overview Table 117. Dr. Reddy's Laboratories Treatment of Blastic-Phase CML Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Dr. Reddy's Laboratories Treatment of Blastic-Phase CML Product Portfolio Table 119. Dr. Reddy's Laboratories Recent Development Table 120. Bristol Myers Squibb Company Information Table 121. Bristol Myers Squibb Business Overview Table 122. Bristol Myers Squibb Treatment of Blastic-Phase CML Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Bristol Myers Squibb Treatment of Blastic-Phase CML Product Portfolio Table 124. Bristol Myers Squibb Recent Development Table 125. Beacon Pharmaceuticals Company Information Table 126. Beacon Pharmaceuticals Business Overview Table 127. Beacon Pharmaceuticals Treatment of Blastic-Phase CML Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Beacon Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolio Table 129. Beacon Pharmaceuticals Recent Development Table 130. Apotex Company Information Table 131. Apotex Business Overview Table 132. Apotex Treatment of Blastic-Phase CML Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Apotex Treatment of Blastic-Phase CML Product Portfolio Table 134. Apotex Recent Development Table 135. Key Raw Materials Table 136. Raw Materials Key Suppliers Table 137. Treatment of Blastic-Phase CML Distributors List Table 138. Treatment of Blastic-Phase CML Customers List Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. Treatment of Blastic-Phase CML Product Image Figure 2. Global Treatment of Blastic-Phase CML Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Treatment of Blastic-Phase CML Market Size (2021-2032) & (US$ Million) Figure 4. Global Treatment of Blastic-Phase CML Sales (2021-2032) & (K Units) Figure 5. Global Treatment of Blastic-Phase CML Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Treatment of Blastic-Phase CML Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Targeted Therapy with TKIs Image Figure 9. Allogeneic BMT or SCT Image Figure 10. Chemotherapy Image Figure 11. Others Image Figure 12. Global Treatment of Blastic-Phase CML Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Treatment of Blastic-Phase CML Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Treatment of Blastic-Phase CML Sales Market Share by Type (2021-2032) Figure 15. Global Treatment of Blastic-Phase CML Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Treatment of Blastic-Phase CML Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Treatment of Blastic-Phase CML Revenue Market Share by Type (2021-2032) Figure 18. Hospitals Image Figure 19. Clinics Image Figure 20. Others Image Figure 21. Global Treatment of Blastic-Phase CML Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Treatment of Blastic-Phase CML Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Treatment of Blastic-Phase CML Sales Market Share by Application (2021-2032) Figure 24. Global Treatment of Blastic-Phase CML Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Treatment of Blastic-Phase CML Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Treatment of Blastic-Phase CML Revenue Market Share by Application (2021-2032) Figure 27. North America Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Treatment of Blastic-Phase CML Sales Market Share by Country (2021-2032) Figure 29. U.S. Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Treatment of Blastic-Phase CML Sales Market Share by Country (2021-2032) Figure 34. Germany Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Treatment of Blastic-Phase CML Sales Market Share by Country (2021-2032) Figure 41. China Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Treatment of Blastic-Phase CML Sales Market Share by Country (2021-2032) Figure 49. Brazil Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Treatment of Blastic-Phase CML Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Treatment of Blastic-Phase CML Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Treatment of Blastic-Phase CML Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Treatment of Blastic-Phase CML Revenue (2021-2032) & (US$ Million) Figure 60. North America Treatment of Blastic-Phase CML Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Treatment of Blastic-Phase CML Revenue (2021-2032) & (US$ Million) Figure 62. Europe Treatment of Blastic-Phase CML Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Treatment of Blastic-Phase CML Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Treatment of Blastic-Phase CML Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Treatment of Blastic-Phase CML Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Treatment of Blastic-Phase CML Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Treatment of Blastic-Phase CML Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Treatment of Blastic-Phase CML Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Targeted Therapy with TKIs
  • Allogeneic BMT or SCT
  • Chemotherapy
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • Qilu Pharmaceutical
  • Lunan Pharmaceutical
  • Hansoh Pharmaceutical
  • HanHui Pharmaceuticals
  • Takeda Pharmaceuticals
  • Sanofi
  • Pfizer
  • Novartis
  • Dr. Reddy's Laboratories
  • Bristol Myers Squibb
  • Beacon Pharmaceuticals
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Treatment of Blastic-Phase CML Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Treatment of Blastic-Phase CML Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Treatment of Blastic-Phase CML Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Treatment of Blastic-Phase CML Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Treatment of Blastic-Phase CML Market Dynamics
  1. 2.1 Treatment of Blastic-Phase CML Industry Trends
  2. 2.2 Treatment of Blastic-Phase CML Industry Drivers
  3. 2.3 Treatment of Blastic-Phase CML Industry Opportunities and Challenges
  4. 2.4 Treatment of Blastic-Phase CML Industry Restraints
3 Treatment of Blastic-Phase CML Market by Manufacturers
  1. 3.1 Global Treatment of Blastic-Phase CML Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Treatment of Blastic-Phase CML Sales by Manufacturers (2021-2026)
  3. 3.3 Global Treatment of Blastic-Phase CML Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Treatment of Blastic-Phase CML Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Treatment of Blastic-Phase CML Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Treatment of Blastic-Phase CML Manufacturers, Product Type & Application
  7. 3.7 Global Treatment of Blastic-Phase CML Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Treatment of Blastic-Phase CML Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Treatment of Blastic-Phase CML Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Treatment of Blastic-Phase CML Tier 1, Tier 2, and Tier 3
4 Treatment of Blastic-Phase CML Market by Type
  1. 4.1 Treatment of Blastic-Phase CML Type Introduction
  2. 4.1.1 Targeted Therapy with TKIs
  3. 4.1.2 Allogeneic BMT or SCT
  4. 4.1.3 Chemotherapy
  5. 4.1.4 Others
  6. 4.2 Global Treatment of Blastic-Phase CML Sales by Type
  7. 4.2.1 Global Treatment of Blastic-Phase CML Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Treatment of Blastic-Phase CML Sales by Type (2021-2032)
  9. 4.2.3 Global Treatment of Blastic-Phase CML Sales Market Share by Type (2021-2032)
  10. 4.3 Global Treatment of Blastic-Phase CML Revenue by Type
  11. 4.3.1 Global Treatment of Blastic-Phase CML Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Treatment of Blastic-Phase CML Revenue by Type (2021-2032)
  13. 4.3.3 Global Treatment of Blastic-Phase CML Revenue Market Share by Type (2021-2032)
5 Treatment of Blastic-Phase CML Market by Application
  1. 5.1 Treatment of Blastic-Phase CML Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Treatment of Blastic-Phase CML Sales by Application
  6. 5.2.1 Global Treatment of Blastic-Phase CML Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Treatment of Blastic-Phase CML Sales by Application (2021-2032)
  8. 5.2.3 Global Treatment of Blastic-Phase CML Sales Market Share by Application (2021-2032)
  9. 5.3 Global Treatment of Blastic-Phase CML Revenue by Application
  10. 5.3.1 Global Treatment of Blastic-Phase CML Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Treatment of Blastic-Phase CML Revenue by Application (2021-2032)
  12. 5.3.3 Global Treatment of Blastic-Phase CML Revenue Market Share by Application (2021-2032)
6 Global Treatment of Blastic-Phase CML Sales by Region
  1. 6.1 Global Treatment of Blastic-Phase CML Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Treatment of Blastic-Phase CML Sales by Region (2021-2032)
  3. 6.2.1 Global Treatment of Blastic-Phase CML Sales by Region (2021-2026)
  4. 6.2.2 Global Treatment of Blastic-Phase CML Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Treatment of Blastic-Phase CML Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Treatment of Blastic-Phase CML Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Treatment of Blastic-Phase CML Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Treatment of Blastic-Phase CML Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Treatment of Blastic-Phase CML Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Treatment of Blastic-Phase CML Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Treatment of Blastic-Phase CML Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Treatment of Blastic-Phase CML Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Treatment of Blastic-Phase CML Revenue by Region
  1. 7.1 Global Treatment of Blastic-Phase CML Revenue by Region
  2. 7.1.1 Global Treatment of Blastic-Phase CML Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Treatment of Blastic-Phase CML Revenue by Region (2021-2026)
  4. 7.1.3 Global Treatment of Blastic-Phase CML Revenue by Region (2027-2032)
  5. 7.1.4 Global Treatment of Blastic-Phase CML Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Treatment of Blastic-Phase CML Revenue (2021-2032)
  8. 7.2.2 North America Treatment of Blastic-Phase CML Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Treatment of Blastic-Phase CML Revenue (2021-2032)
  11. 7.3.2 Europe Treatment of Blastic-Phase CML Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Treatment of Blastic-Phase CML Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Treatment of Blastic-Phase CML Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Treatment of Blastic-Phase CML Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Treatment of Blastic-Phase CML Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing Pharmaceutical
  2. 8.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 8.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 8.1.3 Chia Tai Tianqing Pharmaceutical Treatment of Blastic-Phase CML Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Pharmaceutical Treatment of Blastic-Phase CML Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 8.2 CSPC Ouyi Pharmaceutical
  8. 8.2.1 CSPC Ouyi Pharmaceutical Company Information
  9. 8.2.2 CSPC Ouyi Pharmaceutical Business Overview
  10. 8.2.3 CSPC Ouyi Pharmaceutical Treatment of Blastic-Phase CML Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CSPC Ouyi Pharmaceutical Treatment of Blastic-Phase CML Product Portfolio
  12. 8.2.5 CSPC Ouyi Pharmaceutical Recent Developments
  13. 8.3 Qilu Pharmaceutical
  14. 8.3.1 Qilu Pharmaceutical Company Information
  15. 8.3.2 Qilu Pharmaceutical Business Overview
  16. 8.3.3 Qilu Pharmaceutical Treatment of Blastic-Phase CML Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Qilu Pharmaceutical Treatment of Blastic-Phase CML Product Portfolio
  18. 8.3.5 Qilu Pharmaceutical Recent Developments
  19. 8.4 Lunan Pharmaceutical
  20. 8.4.1 Lunan Pharmaceutical Company Information
  21. 8.4.2 Lunan Pharmaceutical Business Overview
  22. 8.4.3 Lunan Pharmaceutical Treatment of Blastic-Phase CML Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Lunan Pharmaceutical Treatment of Blastic-Phase CML Product Portfolio
  24. 8.4.5 Lunan Pharmaceutical Recent Developments
  25. 8.5 Hansoh Pharmaceutical
  26. 8.5.1 Hansoh Pharmaceutical Company Information
  27. 8.5.2 Hansoh Pharmaceutical Business Overview
  28. 8.5.3 Hansoh Pharmaceutical Treatment of Blastic-Phase CML Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hansoh Pharmaceutical Treatment of Blastic-Phase CML Product Portfolio
  30. 8.5.5 Hansoh Pharmaceutical Recent Developments
  31. 8.6 HanHui Pharmaceuticals
  32. 8.6.1 HanHui Pharmaceuticals Company Information
  33. 8.6.2 HanHui Pharmaceuticals Business Overview
  34. 8.6.3 HanHui Pharmaceuticals Treatment of Blastic-Phase CML Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 HanHui Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolio
  36. 8.6.5 HanHui Pharmaceuticals Recent Developments
  37. 8.7 Takeda Pharmaceuticals
  38. 8.7.1 Takeda Pharmaceuticals Company Information
  39. 8.7.2 Takeda Pharmaceuticals Business Overview
  40. 8.7.3 Takeda Pharmaceuticals Treatment of Blastic-Phase CML Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Takeda Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolio
  42. 8.7.5 Takeda Pharmaceuticals Recent Developments
  43. 8.8 Sanofi
  44. 8.8.1 Sanofi Company Information
  45. 8.8.2 Sanofi Business Overview
  46. 8.8.3 Sanofi Treatment of Blastic-Phase CML Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Treatment of Blastic-Phase CML Product Portfolio
  48. 8.8.5 Sanofi Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Treatment of Blastic-Phase CML Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Treatment of Blastic-Phase CML Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Novartis
  56. 8.10.1 Novartis Company Information
  57. 8.10.2 Novartis Business Overview
  58. 8.10.3 Novartis Treatment of Blastic-Phase CML Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Novartis Treatment of Blastic-Phase CML Product Portfolio
  60. 8.10.5 Novartis Recent Developments
  61. 8.11 Dr. Reddy's Laboratories
  62. 8.11.1 Dr. Reddy's Laboratories Company Information
  63. 8.11.2 Dr. Reddy's Laboratories Business Overview
  64. 8.11.3 Dr. Reddy's Laboratories Treatment of Blastic-Phase CML Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Dr. Reddy's Laboratories Treatment of Blastic-Phase CML Product Portfolio
  66. 8.11.5 Dr. Reddy's Laboratories Recent Developments
  67. 8.12 Bristol Myers Squibb
  68. 8.12.1 Bristol Myers Squibb Company Information
  69. 8.12.2 Bristol Myers Squibb Business Overview
  70. 8.12.3 Bristol Myers Squibb Treatment of Blastic-Phase CML Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bristol Myers Squibb Treatment of Blastic-Phase CML Product Portfolio
  72. 8.12.5 Bristol Myers Squibb Recent Developments
  73. 8.13 Beacon Pharmaceuticals
  74. 8.13.1 Beacon Pharmaceuticals Company Information
  75. 8.13.2 Beacon Pharmaceuticals Business Overview
  76. 8.13.3 Beacon Pharmaceuticals Treatment of Blastic-Phase CML Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Beacon Pharmaceuticals Treatment of Blastic-Phase CML Product Portfolio
  78. 8.13.5 Beacon Pharmaceuticals Recent Developments
  79. 8.14 Apotex
  80. 8.14.1 Apotex Company Information
  81. 8.14.2 Apotex Business Overview
  82. 8.14.3 Apotex Treatment of Blastic-Phase CML Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Apotex Treatment of Blastic-Phase CML Product Portfolio
  84. 8.14.5 Apotex Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Treatment of Blastic-Phase CML Value Chain Analysis
  2. 9.1.1 Treatment of Blastic-Phase CML Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Treatment of Blastic-Phase CML Production Mode & Process
  6. 9.2 Treatment of Blastic-Phase CML Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Treatment of Blastic-Phase CML Distributors
  9. 9.2.3 Treatment of Blastic-Phase CML Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst